Dow Pharmaceutical Sciences, Inc.

Sudo Biosciences Limited

Arcutis Biotherapeutics, Inc.

Iolyx Therapeutics, Inc.

Bhaskar Chaudhuri

David W Osborne

Anjali Pandey

Gordon J Dow

Athisayamani Jeyaraj Duraiswamy

Gregory Dietsch

Sukesh Kalva

Mahesh Thakkar

Gordon Jay Dow

Seetharaman Manojveer

Barry Calvarese

Hovhannes John Gukasyan

Archie W Thurston, Jr

David Wade Osborne

Described herein are compounds of Formula (I) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.

Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors

Methods for the ophthalmic delivery of roflumilast. The inventors have made the surprising discovery that the administration of pharmaceutical compositions comprising roflumilast to the cornea preferentially delivers the drug laterally through the ocular surface and anterior tissues of the eye. In contrast to the delivery of roflumilast to the skin, which primarily travels transversely through the various tissues of the skin, or many other topical ocular pharmaceutical compositions which travel through the cornea to the aqueous humor, the delivery of drug to the eye to the cornea travels laterally to the ocular surface and anterior tissues of the eye. Such methods can result in elevated levels of the drug in the cornea and other ocular surface and anterior tissues of the eye (e.g., iris-ciliary body, sclera, conjunctiva, and aqueous humor) relative to the interior or posterior tissues of the eye.

Methods for ophthalmic delivery of roflumilast

Described herein are compounds of Formula (XVII) that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of Using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity. 

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.

Topical roflumilast formulation having improved delivery and plasma half life

Azithromycin has increased efficacy in treating acne and other skin conditions when administered systemically at low doses, below those previously known to produce a clinical antibiotic effect.

Azithromycin for treatment of skin disorders

Azithromycin, administered systemically, is an effective treatment for nodules associated with acne vulgaris.

Growing community of inventors

San Jose, CA, United States of America

Bhaskar Chaudhuri